Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Zymeworks Inc. (NYSE: ZYME) announced that Neil Josephson, M.D., will transition from interim Chief Medical Officer to permanent CMO on November 15, 2021. Dr. Josephson has led Zymeworks’ medical organization since May and is tasked with advancing the clinical pipeline, including the pivotal trial enrollment for zanidatamab in treating HER2-positive gastroesophageal adenocarcinomas. Zymeworks focuses on developing multifunctional biotherapeutics, with zanidatamab and ZW49 as its lead candidates, while expanding its preclinical pipeline and strategic partnerships.
Zymeworks (NYSE: ZYME) has initiated the HERIZON-GEA-01 Phase 3 clinical trial to assess zanidatamab combined with chemotherapy for first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). This pivotal study aims to enroll around 700 patients across 300 sites globally, with results expected as early as 2024 for a supplemental Biologics License Application (BLA). Previous Phase 2 data indicated a confirmed objective response rate of 75% for zanidatamab plus chemotherapy, signaling potential for blockbuster therapeutic status.
Zymeworks Inc. (NYSE: ZYME) has announced its participation in three upcoming investor conferences, showcasing its development of multifunctional biotherapeutics.
- At the Stifel 2021 Virtual Healthcare Conference on November 16-17, a fireside chat will occur on November 17 at 1:20 p.m. ET.
- The Jefferies London Healthcare Conference will feature a pre-recorded presentation available on November 18.
- A fireside chat at the Evercore ISI HEALTHCONx Virtual Conference is scheduled for November 30 at 3:05 p.m. ET.
These events will be webcast and available for replay on Zymeworks' website.
Zymeworks reported Q3 2021 financial results, showcasing revenue of $4.4 million, up from $2.6 million in Q3 2020, attributed to milestone payments and R&D support. R&D expenses decreased to $49.9 million from $54.4 million year-over-year, while G&A expenses fell to $15.5 million from $21.9 million. Net loss improved to $60.6 million from $72.6 million in the same period last year. Zymeworks holds $307.8 million in cash resources, expected to fund operations into late 2022. The company advances its clinical programs and prepares for pivotal trials.
Zymeworks Inc. (NYSE:ZYME) has announced a conference call and webcast on November 9 at 4:15 p.m. ET, detailing the launch of its Phase 3 HERIZON-GEA-01 study for zanidatamab in treating HER2-positive gastroesophageal adenocarcinoma (GEA). The study compares zanidatamab plus chemotherapy with the standard trastuzumab plus chemotherapy. Zanidatamab, a bispecific antibody, has received several FDA designations, including Breakthrough Therapy and Fast Track, indicating its potential in the treatment landscape for solid tumors expressing HER2.
Zymeworks Inc. (NYSE: ZYME) and ALX Oncology Holdings Inc. (NASDAQ: ALXO) have initiated a Phase 1b/2 clinical trial, dosing the first patient to assess the safety and efficacy of zanidatamab combined with evorpacept for advanced HER2-positive breast and solid tumors. This combination aims to improve immune clearance of cancer cells. Zanidatamab, a bispecific antibody, is designed to target HER2, while evorpacept blocks the CD47 pathway, potentially enhancing therapeutic effects. This collaboration follows promising results from prior studies involving evorpacept in gastric cancers.
Zymeworks Inc. (NYSE: ZYME) has announced promising clinical results for zanidatamab, a HER2-targeted therapy for first-line HER2-positive gastroesophageal adenocarcinoma (GEA). Data from a Phase 2 study presented at the ESMO Congress showed a confirmed objective response rate (cORR) of 75%, and 93% for the proposed Phase 3 regimen. The median duration of response was 16.4 months. A global Phase 3 trial is planned to start in Q4 2021, which aims to establish zanidatamab as a new standard of care in combination with chemotherapy.
Zymeworks Inc. (NYSE: ZYME) announced new clinical data for zanidatamab, a HER2-targeted bispecific antibody, showing promising results in treating first-line HER2-expressing gastroesophageal adenocarcinoma (GEA). In a trial involving 30 patients, the objective response rate was 68.2%, and the disease control rate reached 90.9%. The updated data will be presented at the ESMO Annual Congress on September 16. Zymeworks is positioning zanidatamab as a foundational HER2-targeted therapy, supported by FDA designations for accelerated approval.
Zymeworks Inc. (NYSE: ZYME) reported second-quarter 2021 financial results, with revenue of $1.8 million, down from $12.4 million in Q2 2020. The net loss increased to $67.5 million compared to $39.0 million last year, attributed to decreased revenue and increased expenses. The company is preparing for pivotal trials for zanidatamab in HER2-positive cancer and has initiated new clinical studies. Despite the challenges, Zymeworks maintains $359.8 million in cash, projecting operational funding into 2022.
Zymeworks Inc. (NYSE: ZYME) announced that Janssen Biotech has dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks' Azymetric™ and EFECT™ platforms. This milestone is part of their 2017 licensing agreement, in which Zymeworks received an upfront payment of $50 million and could earn up to $282 million in development and $1.12 billion in commercial milestones. Zymeworks emphasizes the significance of its platform technologies to their business model, complementing their leading clinical assets.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
